Make Yahoo Your Homepage
Discover something new every day from News, Sports, Finance, Entertainment and more!
Follow the latest developments here
Lisbet Stone was turned away from her flight to London due to having an outdated Covid test.
The global laboratory proficiency testing market size is expected to reach USD 1.9 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2020 to 2027. The market is driven by the increasing focus on water tests, legalization of medical cannabis, a growing number of cannabis testing laboratories, and increasing outbreaks of foodborne illnesses.
Aker ASA ("Aker") today announced that its wholly owned subsidiary, Aker Horizons AS ("Aker Horizons"), has agreed to acquire 75 percent of Mainstream Renewable Power ("Mainstream"), a leading independent renewable energy company within onshore and offshore wind and solar (the "Transaction"). The Transaction values the current equity of Mainstream at EUR 900 million on a 100 percent basis and gives Aker Horizons a portfolio of projects in operation and under construction of about 1.4 GW, a project development pipeline of about 10 GW and a further 10 GW of identified project opportunities.
"There's just so much ugly garbage to sift through before you can make a decision," admitted Daniel Dale.
The business lobby group calls for the extension of support schemes for firms affected by Covid.
(Bloomberg) -- The European Union will unveil its plan on Tuesday to strengthen the international role of the euro as it seeks to erode the dominance of the U.S. dollar and to insulate the bloc from financial risks, including U.S. sanctions.The European Commission blueprint will outline how the region can fortify its economic and financial resilience by bolstering the single currency’s architecture and through growing markets like green finance, according to a draft of the plan seen by Bloomberg.Calls to boost the bloc’s autonomy have been growing for years and gained steam after the U.S. imposed sanctions against Iran that would also punish European banks, companies and people who do business with the Islamic republic. The commission’s plan reflects increasing pressure by member states for the EU to adopt tools that will allow it to pursue its foreign-policy goals with less recourse to an unpredictable U.S. ally.The U.S.’s ability to enforce international sanctions because of the dollar’s power “has seriously affected the EU’s and its member states’ ability to advance foreign policy objectives,” the draft document says. Policy made in Washington has, at times, “compromised legitimate trade and investment of EU businesses.”Volatile AllyThe initiative to boost the role of the euro was first put on the EU’s agenda by former European Commission President Jean-Claude Juncker, who, faced with an erratic partner in Washington, called for steps to shield the region’s economies and currency from volatility elsewhere in the world. It was during Juncker’s term, in 2018, that President Donald Trump pulled the U.S. out of the international accord that restricted Iran’s nuclear program and reimposed sanctions.The U.S. has also crippled one of Europe’s signature energy infrastructure projects, Nord Stream 2, by threatening businesses with sanctions. The American measures are seen as a way to boost U.S. liquefied natural gas exports to Europe while also maintaining the fuel’s transit through eastern European nations that don’t use the euro but are friendly with Washington.According to the European Central Bank, the euro remains the second most-used currency in the world behind the dollar. But despite the latest push, there’s little the EU can do in terms of policy or legislative initiatives to meaningfully boost the use of its currency.A main focus for the EU will be to complete flagship projects that will better unify its banking sector and capital markets. These initiatives have stalled, however, often due to entrenched disagreements between governments.Sustainable FinanceYet the EU thinks its landmark recovery fund, designed to help countries rebound from the pandemic-induced recession, could help buttress the euro. The stimulus package will provide 750 billion euros ($905 billion) in grants and loans, raised by jointly backed debt, while a third of these funds will have to be spent toward green projects.“Promoting sustainable finance is an opportunity to develop EU financial markets into a global ‘green finance’ hub, bolstering the euro as the default currency for the denomination of sustainable financial products,” the draft plan said.In 2019, almost half of all global green bond issuance, including that originating outside the bloc, was denominated in euros, according to the EU’s executive arm, and this figure is expected to rise, as the commission is poised to issue over 250 billion euros in green debt starting this year. The securities are meant to fund EU’s recovery plan.The plan would see the commission raise almost a trillion euros in debt until 2026, making it one of the biggest sovereign issuers in the world with a stellar credit rating. In parallel, “the Commission will further support the development of euro-denominated commodity derivatives for energy and raw materials and will facilitate the emergence of euro-denominated benchmark indices and trading venues covering core sectors, including nascent energy markets, such as hydrogen.”Digital PushAnother development that could also prove a game changer in that area is the ECB’s push for the introduction of a digital euro, the paper said. “Further development of the European digital finance sector will reinforce the EU’s open strategic autonomy in financial services and the capacity to protect the EU’s financial stability and values.”Brexit is also pushing the EU to bolster its financial infrastructure. The commission stepped up pressure on companies to move parts of their derivatives-clearing business from London to inside the EU. It will set up a working group to assess possible technical issues that could pose an obstacle in this regard, it said.“We need a clear step-by-step masterplan that helps key financial sector businesses move from the United Kingdom to the European Union,” said Markus Ferber, a lawmaker in the European Parliament. “A mere ‘wait and see’ approach will not do to bolster European financial markets.”(Updates with Nord Stream 2 in the sixth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
(Bloomberg) -- Brent oil rose past $55 a barrel -- with some assistance from a weakening dollar -- as the growing popularity of commodities outweighed signs that a resurgence of the coronavirus in Asia is starting to impact demand.Futures in London climbed as much as 1.2% after falling around 3% over the previous two sessions. Investors have rushed back into the crude market this year, with total holdings of Brent and West Texas Intermediate futures at the highest since May. The move is being driven by expectations for energy demand to recover as vaccines are rolled out and as several bigs banks recommend commodities as a hedge against a likely acceleration in inflation.Crude is rising even as government calls for Chinese citizens not to travel over the Lunar New Year holidays stoke concern that Asian demand will take a near-term hit. Much of Japan is also under a state of emergency, while Indian energy consumption has gotten off to a shaky start to the new year.After a scorching start to 2021 as Saudi Arabia announced unilateral output cuts, oil’s rally has run out of steam over the past few sessions as more virus lockdowns and travel restrictions sap short-term demand. The International Energy Agency is due to release its monthly report on the global oil market later on Tuesday.“Although the dollar is largely dictating market direction at the moment, there could be more volatility with the IEA report,” said Warren Patterson, head of commodities strategy at ING Bank NV. “Demand estimates will be of interest, given the wave of lockdowns we have seen over the last month or so.”The market is now looking ahead to the inauguration on Wednesday of U.S. President-elect Joe Biden, who is proposing a $1.9 trillion Covid-19 relief package that promises to boost the economy and energy demand if passed.Oil’s futures curve shows sentiment is mixed. Brent’s prompt timespread is 3 cent a barrel in backwardation, a bullish market structure where near-dated prices are higher than later-dated ones. It was 3 cents in contango on Friday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The news comes amid a growing row over quarantine rules for the players ahead of the tournament.
BBC crime drama "will continue in another form” beyond TV series, says creator.
Follow the latest updates
Dublin, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The "E-bike Market in Europe 2021-2025" report has been added to ResearchAndMarkets.com's offering. The e-bike market in Europe is poised to grow by 6654.33 th units during 2021-2025 progressing at a CAGR of 20% during the forecast period. The report on e-bike market in Europe provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as key vendor analysis.The market is driven by the increasing concern toward health and environment among consumers, rising demand for eco-friendly transportation and continuous reduction in battery costs. This study identifies the development of technologically advanced and lightweight e-bikes as one of the prime reasons driving the e-bike market in Europe during the next few years. Also, the development of an anti-lock braking system for e-bikes and the flooding of Chinese e-bikes into the European market will lead to sizable demand in the market.The e-bike market in Europe market analysis includes technology segment, product segment and geographical landscapes.The e-bike market in Europe is segmented as below:By Technology Lithium-Ion BatterySealed Lead Acid Battery By Product PedelecsS-Pedelecs By Geographical Landscapes GermanyThe NetherlandsFranceRest of Europe The report covers the following areas: E-bike market in Europe sizingE-bike market in Europe forecastE-bike market in Europe industry analysis The robust vendor analysis included in the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading e-bike market in Europe vendors that include Accell Group NV, BH BIKES EUROPE SL, Derby Cycle Holding GmbH, Georg Fritzmeier GmbH & Co. KG, Giant Manufacturing Co. Ltd., Klever Mobility Europe GmbH, LEADER Ltd., Riese & MAller GmbH, Yamaha Motor Co. Ltd., and Zhejiang Luyuan Electric Vehicle Co. Ltd.. Key Topics Covered: Executive Summary Market Overview Market Landscape Market ecosystemValue chain analysis Market Sizing Market definitionMarket segment analysisMarket size 2020Market outlook: Forecast for 2020-2025 Five Forces Analysis Five forces summaryBargaining power of buyersBargaining power of suppliersThreat of new entrantsThreat of substitutesThreat of rivalryMarket condition Market Segmentation by Product Market segmentsComparison by ProductPedelecs - Market size and forecast 2020-2025S-pedelecs - Market size and forecast 2020-2025Market opportunity by Product Market Segmentation by Technology Market segmentsComparison by TechnologyLithium-ion battery - Market size and forecast 2020-2025Sealed lead acid battery - Market size and forecast 2020-2025Market opportunity by Technology Market Segmentation by Platform Urban e-bikesTrekking e-bikeseMTBsCargo e-bikesOthers Customer LandscapeGeographic Landscape Geographic segmentationGeographic comparisonGermany - Market size and forecast 2020-2025The Netherlands - Market size and forecast 2020-2025France - Market size and forecast 2020-2025Rest of Europe - Market size and forecast 2020-2025Market opportunity by geographyMarket driversMarket challengesMarket trends Vendor Landscape OverviewVendor landscapeLandscape disruption Vendor Analysis Vendors coveredMarket positioning of vendorsAccell Group NVBH BIKES EUROPE SLDerby Cycle Holding GmbHGeorg Fritzmeier GmbH & Co. KGGiant Manufacturing Co. Ltd.Klever Mobility Europe GmbHLEADER Ltd.Riese & Muller GmbHYamaha Motor Co. Ltd.Zhejiang Luyuan Electric Vehicle Co. Ltd. For more information about this report visit https://www.researchandmarkets.com/r/336bvj About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Footage shared to Instagram on January 8 captures the heartfelt moment a law school graduate found out he passed the California Bar Exam.Omarr Rambert, a recent UCLA School of Law graduate, decided in fifth grade he wanted to be a lawyer and described passing the exam as “the greatest accomplishment” of his life.“I was the first male in my family to go to college, let alone law school,” he said.Rambert lost his stepfather, the songwriter LaShawn Daniels, in a fatal car crash in 2019, during his final year of law school. Despite the pain of losing of one of his “biggest supporters,” he pushed on and finished “the mission because that’s what [Daniels] wanted.”“I graduated UCLA School of Law that same year, had a virtual graduation ceremony because of COVID-19, and began the process of studying for the California Bar Exam,” he said. “The CA Bar Exam is considered the hardest in the nation, and I passed due to God and hard work.”This video shows Rambert and his mother emotionally reacting to the news of his exam results. Credit: Omarr Rambert via Storyful
Sacha Fenestraz will occupy the TOM’S Toyota SUPER GT seat that has been vacated by Nick Cassidy for the 2021 season, Motorsport.com understands.
Harden registered 34 points, 12 assists and six rebounds.
Italian government bond yields were lower on Tuesday, ahead of a confidence vote in the upper house Senate that could force prime minister Giuseppe Conte to resign. Conte won a confidence vote in the Chamber of Deputies on Monday as he clung to power after a junior partner quit the ruling coalition and triggered a political crisis.
Municipality Finance Plc Stock exchange release 19 January 2021 at 10:30 am (EET) Municipality Finance issues USD 1.5 billion benchmark under MTN programme Municipality Finance Plc issues USD 1.5 billion benchmark on 20 January 2021. The maturity date of the benchmark is 20 March 2026. The benchmark bears interest at a fixed rate of 0.625 % per annum. The benchmark is issued under MuniFin’s EUR 40 billion programme for the issuance of debt instruments. The offering circular and the supplemental offering circular are available in English on the company's website at www.munifin.fi/investor-relations. MuniFin has applied for the benchmark to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 20 January 2021. BofA Securities, Goldman Sachs International, J.P. Morgan and TD Securities act as the Joint Lead Managers for the issue of the notes. MUNICIPALITY FINANCE PLCFurther information: Joakim HolmströmExecutive Vice President, Capital Markets and Corporate Responsibilitytel. +358 9 6803 5674 MuniFin (Municipality Finance Plc) is one of Finland's largest credit institutions: the company's balance sheet totals approximately EUR 41 billion. The company is owned by Finnish municipalities, the public sector pension fund Keva and the Republic of Finland. MuniFin's mission is to build a better future in line with the principles of responsibility and in cooperation with its customers. MuniFin's customers are Finnish municipalities, municipal federations, municipally controlled entities and non-profit housing organisations. Lending is used for environmentally and socially responsible investment targets such as public transportation, sustainable buildings, hospitals and healthcare centres, schools and day care centres, and homes for people with special needs. MuniFin's customers are domestic but the company operates in a completely global business environment. It is the most active Finnish bond issuer in international capital markets and the first Finnish green and social bond issuer. The funding is exclusively guaranteed by the Municipal Guarantee Board. The Municipality Finance Group also includes the subsidiary company, Financial Advisory Services Inspira Ltd. Read more: www.munifin.fi Important Information The information contained herein is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into any such country or jurisdiction or otherwise in such circumstances in which the release, publication or distribution would be unlawful. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any securities or other financial instruments in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. This communication does not constitute an offer of securities for sale in the United States. The notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or under the applicable securities laws of any state of the United States and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.
BOC Group today announced ADOIT 12.0, a major update of their EA suite, packing all powerful features in a clean, elegant design that makes every step feel faster and more responsive than ever, and introduced Lean EA that lifts ADOIT to an entirely new level of power and flexibility.
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease Research academic teams of the consortium - Institut de Recherche Saint Louis1 & Institut Mondor de Recherche Biomédicale 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and life-threatening disease Lyon, France – 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery (“NOVA”) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease (GvHD), the main complication that may occur after an allogeneic hematopoietic stem cell transplantation. The ambition of the Silikotac Program is to create the first French industrial and scientific immunotherapy chain group focused on GvHD. This financing is part of the PSPC (Projet de recherche et développement Structurant pour la Compétitivité) program fund from Bpifrance, a financing initiative from the French government to support new and emerging industries within France. ElsaLys Biotech is a clinical stage company developing inolimomab, an immunotherapy product, for steroid-refractory acute graft-versus-host disease in adult and paediatric populations. NOVA is a leading health tech company using in silico proprietary technology to optimize clinical trial development and predict drug efficacy. NOVA, which has been awarded €2.4 million, will conduct in silico clinical trials utilising its innovative Jinkō® platform. The results will be used to support future regulatory approval applications by ElsaLys for inolimomab in Europe. Jinkō® is NOVA’s best-in-class clinical trial simulation and disease modelling platform. Its workflows are designed to closely resemble those of real-life clinical studies. The two academic teams in the Silikotac consortium, from Institut de Recherche Saint Louis & Institut Mondor de Recherche Biomédicale, have been awarded €0.95 million to: Further deepen the in vitro mechanism of action of inolimomab at molecular and cellular levelEvaluate new protocols for broadening and optimizing inolimomab use in the GvHD algorithm treatment using several in vivo preclinical models ElsaLys announced in July 2020 the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for inolimomab for the treatment of Steroid-Refractory acute graft-versus-host disease (aGvHD) in grade II-IV adult patients. In Europe, the French National Agency for the Medicines and Health Products Safety (ANSM) granted a Temporary Authorisation for Use (ATU) for inolimomab renewed at the end of 2020. Inolimomab is therefore available in France to adults and paediatric patients over 28 days of age for the treatment of acute steroid-refractory or steroid-dependent graft-versus-host disease. Further early access applications will be submitted in other European countries while ElsaLys continues to work on the filing of marketing approval in Europe and the US. Dr. Christine Guillen, CEO and Co-founder, ElsaLys Biotech, said: “Patient numbers for rare diseases are limited and simulating clinical trials in a virtual population can help strengthen data packages submitted for regulatory approval. We are engaged, like regulatory agencies are, in using in silico trials for ethical concern and we think this approach can be key to accelerate the development of innovative drugs, notably in paediatric population.” François-Henri Boissel, CEO, NOVA, said: “We are excited to be leveraging Jinkō®, our unique simulation platform, to support ElsaLys in bringing an important treatment to patients. NOVA’s mission is to help companies enhance their R&D activities and optimize outcomes for patients. The use of in silico trials is relatively new, but regulatory authorities are working towards providing a framework for expanded use as a third pillar of the R&D drug paradigm in addition to in vitro and in vivo approaches.” Ends For more information, please contact: Novadiscovery François-Henri Boissel, Chief Executive Officercontact@novadiscovery.com Consilium Strategic Communications Sukaina Virji, Melissa Gardiner, Carina JursEmail: novadiscovery@consilium-comms.com ElsaLys BiotechDr. Christine Guillen, CEO and Co-founder +33 (0)4 37 28 73 00guillen@elsalysbiotech.com ATCG Partners Marie Puvieux (France) +33 (0)6 10 54 36 72Céline VOISIN (UK/US) +33 (0)6 62 12 53 39presse@atcg-partners.com About inolimomab Inolimomab is an anti-IL-2 Rα monoclonal antibody active as an immunotherapy product for the treatment of steroid-refractory acute GvHD.In acute GvHD, activated T cell lymphocytes from the allograft’s donor recognize and attack recipient tissues. T cell lymphocyte activation and proliferation is governed by the key IL-2/IL-2 receptor (IL-2 R) pathway.By recognizing the subunit α of the IL-2 Receptor complex (IL-2 Rα) which is upregulated on T cells upon activation, inolimomab blocks the binding of the cytokine IL-2 on IL-2 Rα thereby inhibiting IL-2 signalling and donor T cell proliferation.The efficacy of inolimomab in aGvHD relies on its specific potent immunosuppression on T cell lymphocytes through the blocking of the IL-2/IL-2 Rα pathway triggering the disease. About steroid-resistant aGvHDFormerly called bone marrow transplant, Hematopoietic Stem Cell Transplantation (HSCT) is the last therapeutic option for patients with certain blood cancers or severe immunodeficiency. In practice, the treatment is designed to replace the diseased blood cells of the patient with the hematopoietic stem cells of a matching donor (allograft).Once grafted, these stem cells will produce new healthy and functional blood cells, including white blood cells that will allow patients to bridge their immune deficiency or to eliminate surviving cancer cells. If this technique has made considerable progress in 60 years, half of transplant recipients are still victims of complications: side effects of conditioning treatments, immunosuppressive treatments before allograft (that aims to prevent transplant rejection), long-term susceptibility to infections and GvHD. In the latter case, the donor’s over-active T-cells «turn against» the patient’s tissues: mucous membranes, skin, gastro-intestinal tract, liver and lungs. The acute form appears just after the transplant, the chronic form occurring several months later (preceded or not by an acute GvHD episode). Affecting between 30 to 50% of patients, GvHD is the main complication of hematopoietic stem cell transplantation. To halt this disease, physicians use corticosteroids. The fact remains that some 30 to 50% of aGvHD patients are refractory or dependent to the steroid treatment. To date limited therapeutic options are available for these patients with no standard treatment approved so far in Europe and only one in the US. About ElsaLys BiotechElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases.Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs.Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Stay in touch with ElsaLys Biotech and directly receive our press releases by filling our contact form on www.elsalysbiotech.com Follow us on Twitter: @ElsalysBiotech and on linkedin.com/company/elsalys-biotech/ About Novadiscovery NOVA is a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development. The Company aims to improve R&D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials. NOVA’s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform, Jinkō®. NOVA is headquartered in Lyon, France and has a team of 40 scientists, engineers & clinicians who work at the interface of biology, pharmacology, mathematics & computer science. For more information, please visit https://www.novadiscovery.com and follow us on Twitter @novadiscovery and linkedin.com/company/novadiscovery 1 Institut de Recherche Saint Louis, Pr Vassili Soumelis, Unité 976, Inserm and Université de Paris 2 Institut Mondor de Recherche Biomédicale, Pr José Cohen, Unité 955, Inserm and Université de Paris Est Créteil
Bid date, 2021-01-19Auction date2021-01-19Settlement date2021-01-20Maturity Date2021-01-27Nominal amount380 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume380 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term889 billion SEKExpected excess liquidity at full allotment509 billion SEK Stockholm, 2021-01-19
